Literature DB >> 10586163

Respiratory syncytial virus and subsequent lower respiratory tract infections in developing countries: A new twist to an old virus.

E A Simoes.   

Abstract

Entities:  

Mesh：

Year:  1999        PMID： 10586163     DOI： 10.1016/s0022-3476(99)70079-x

Source DB:  PubMed          Journal:  J Pediatr        ISSN： 0022-3476            Impact factor:   4.406


× No keyword cloud information.
  5 in total

1.  Respiratory viruses augment the adhesion of bacterial pathogens to respiratory epithelium in a viral species- and cell type-dependent manner.

Authors:  Vasanthi Avadhanula; Carina A Rodriguez; John P Devincenzo; Yan Wang; Richard J Webby; Glen C Ulett; Elisabeth E Adderson
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

2.  Viral load drives disease in humans experimentally infected with respiratory syncytial virus.

Authors:  John P DeVincenzo; Tom Wilkinson; Akshay Vaishnaw; Jeff Cehelsky; Rachel Meyers; Saraswathy Nochur; Lisa Harrison; Patricia Meeking; Alex Mann; Elizabeth Moane; John Oxford; Rajat Pareek; Ryves Moore; Ed Walsh; Robert Studholme; Preston Dorsett; Rene Alvarez; Robert Lambkin-Williams
Journal:  Am J Respir Crit Care Med       Date:  2010-07-09       Impact factor: 21.405

Review 3.  Human genetic factors and respiratory syncytial virus disease severity.

Authors:  Isao Miyairi; John P DeVincenzo
Journal:  Clin Microbiol Rev       Date:  2008-10       Impact factor: 26.132

4.  Inhibition of T1/ST2 during respiratory syncytial virus infection prevents T helper cell type 2 (Th2)- but not Th1-driven immunopathology.

Authors:  G Walzl; S Matthews; S Kendall; J C Gutierrez-Ramos; A J Coyle; P J Openshaw; T Hussell
Journal:  J Exp Med       Date:  2001-04-02       Impact factor: 14.307

5.  Improved clinical and economic outcomes in severe bronchiolitis with pre-emptive nCPAP ventilatory strategy.

Authors:  Sandrine Essouri; Marie Laurent; Laurent Chevret; Philippe Durand; Emmanuelle Ecochard; Vincent Gajdos; Denis Devictor; Pierre Tissières
Journal:  Intensive Care Med       Date:  2013-10-25       Impact factor: 17.440
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.